Molecular Network Characteristics of Phlegm-heat Syndrome in Ischemic Stroke Based on Multi-omics Integrated Analysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

24 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-14

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The molecular characteristics of ischemic stroke with phlegm-heat syndrome and candidate biomarkers were identified based on multi-omics data. The main purpose of this study is to validate the molecular characteristics and biomarkers of phlegm-heat syndrome in ischemic stroke, and to demonstrate the association of biomarkers with clinical outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Molecular Characteristics of Phlegm-heat Syndrome in Ischemic Stroke

NCT06470477

Ischemic Stroke, Acute

NOT_YET_RECRUITING

The Biological Basis of Phlegm Dampness Syndrome in Patients With Ischemic Stroke：A Saliva and Urine Proteomics Study

NCT04472754

Protein; Disease

UNKNOWN

Pulmonary Infection After Ischemic Stroke

NCT05923034

Had a Computed Tomography Scan of the Chest Within 24 Hours After Stroke Onset

UNKNOWN

Construction and Validation of an In-hospital Mortality Risk Prediction Model for Acute Ischemic Stroke Patients

NCT04979624

Acute Ischemic Stroke

UNKNOWN

Development and Validation of the Prediction Model for Cognitive Impairment

NCT05465980

Stroke, Acute

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a cohort study in patients with ischemic stroke. The demographic characteristics, TCM syndromes, and other baseline information will be recorded. At the same time, baseline peripheral blood will be collected. These participants will be followed up to 90 days of onset, and 90-day modified Rankin scale (mRS) scores will be assessed. The collected blood samples will be tested by multi-factor detection technology for candidate biomarkers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phlegm-heat syndrome in ischemic stroke

Phlegm-heat syndrome: the score of "Phlegm-dampness syndrome" ≥10 with the score of "Internal fire syndrome" ≥10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke

No interventions assigned to this group

Non-phlegm-heat syndrome in ischemic stroke

Non-phlegm-heat syndrome: the score of "Phlegm-dampness syndrome" \<10 with the score of "Internal fire syndrome" \<10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke

No interventions assigned to this group

Healthy subjects

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute ischemic stroke, were confirmed by magnetic resonance imaging (MRI).
* Symptom onset within 72 hours.
* Diagnosis of phlegm-heat syndrome or non-phlegm-heat syndrome.
* Male or female ≥ 50 years and ≤ 80 years.
* With written informed consent.

Exclusion Criteria

* Planned or already receiving intravenous thrombolysis or endovascular treatment.
* Acute infectious diseases or acute exacerbations of chronic diseases within one month before enrollment.
* Patients with previous stroke.
* Renal or hepatic insufficiency, tumors, immune diseases, severe underlying diseases.
* Other conditions that may affect the collection and evaluation of clinical information (e.g., severe aphasia, mental illness).

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes